We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nasal Test Developed to Diagnose Creutzfeldt-Jakob Disease

By LabMedica International staff writers
Posted on 19 Aug 2014
A nasal brush test has been developed that can rapidly and accurately diagnose Creutzfeldt-Jakob disease (CJD), an incurable and ultimately fatal neurodegenerative disorder.

Definite diagnosis of sporadic CJD in living patients remains a challenge as up to now, a definitive CJD diagnosis requires testing brain tissue obtained after death or by biopsy in living patients.

An international team of scientists led by those at the National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) studied 31 nasal samples from patients with CJD and 43 nasal samples from patients who had other neurologic diseases or no neurologic disease at all. More...
They obtained olfactory mucosa samples by using a nasal tampon, a rigid fiberoptic rhinoscope, enveloped with a disposable sheath, the Slide-On EndoSheath System (Medtronic Xomed; Minneapolis, MN, USA) and a sterile, disposable brush was then inserted alongside the fibroscope, gently rolled on the mucosal surface and withdrawn, and processed.

An in vitro PrPCJD amplification technology, designated real-time quaking-induced conversion (RT-QuIC), has been shown to have considerable promise as a highly specific diagnostic test for sporadic Creutzfeldt–Jakob disease. Testing with RT-QuIC correctly identified 30 of the 31 CJD patients (97% sensitivity) and correctly showed negative results for all 43 of the non-CJD patients (100% specificity). By comparison, tests using cerebral spinal fluid which is currently used to detect sporadic CJD were 77% sensitive and 100% specific, and the results took twice as long to obtain.

Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, said, “This exciting advance, the culmination of decades of studies on prion diseases, markedly improves on available diagnostic tests for CJD that are less reliable, more difficult for patients to tolerate, and require more time to obtain results. With additional validation, this test has potential for use in clinical and agricultural settings.” The study was published on August 7, 2014, in the New England Journal of Medicine (NEJM).

Related Links:

US National Institute of Allergy and Infectious Diseases
Medtronic Xomed



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
Hematology Consumables
Bioblood Devices
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Molecular Diagnostics

view channel
Image: Researchers found that tumor DNA fragments in blood can reveal ongoing prostate cancer growth even when current tests show little change (image credit: Adobe Stock)

Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer

Prostate cancer is the most common cancer in the U.K., with more than 64,000 men diagnosed and 12,000 deaths each year. For the roughly 10,000 men annually with advanced disease, early assessment of treatment... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.